SOURCE: Protectus Medical Devices, Inc.

July 01, 2010 10:29 ET

Protectus Medical Devices Engages The Investor Relations Group

Active Investor Outreach to Build Company Awareness

MINNEAPOLIS, MN--(Marketwire - July 1, 2010) -  Protectus Medical Devices, Inc. (OTCQB: PTMD) (PINKSHEETS: PTMD), which designs, engineers, and manufactures safety needle devices to protect healthcare workers from accidental needlestick injuries, has engaged The Investor Relations Group ("IRG"), a thirteen-year-old, award-winning, corporate communications firm based in New York City, to serve as its investor relations agency.

IRG's investor relations team will target specific portfolio managers and equity analysts in the global investment community to increase awareness of Protectus Medical Devices' line of products and services.

Dr. John Salstrom, President, CEO and Director of Protectus Medical Devices, stated, "Protectus has outlined a bold set of initiatives for the rest of 2010, and we are confident that IRG will have a great story to tell to the investment community. The dangers of accidental needle stick injuries to healthcare workers are significant, and currently result in unacceptably high costs borne by those who are injured. Our goal is to reduce those costs via the innovation, production, and distribution of devices -- including our lead product, the Protectus Safety Syringe -- that should significantly reduce needlestick injuries sustained within the healthcare environment. We look forward to working with IRG as we achieve our objectives and will update the investment community as we move ahead."

The Investor Relations Group was recently honored with a "Stevie Award" for Investor Relations Program of the Year and named a finalist in the Best Media Website category from the 2009 American Business Awards.

About Protectus Medical Devices, Inc.

Protectus Medical Devices, Inc. (OTCQB: PTMD) (PINKSHEETS: PTMD) designs, engineers, and manufactures safety needle devices to protect healthcare workers from accidental needle injuries. It offers Protectus Safety Syringe (formerly SquareOne Safety Syringe), a patented, automatic, self-sheathing hypodermic safety syringe designed to reduce or eliminate the dangers of accidental needlestick injuries to medical professionals worldwide who may be pricked, scraped or injected by a needle before or after it has been injected and withdrawn from patients potentially carrying infectious bloodborne microorganisms. The company has received 510(k) permission from the US FDA to manufacture and market its Safety Syringe in the US. No other permissions are required to manufacture and market the device. The company was founded in 1999 and is based in Minneapolis, Minnesota.

For more information please visit www.protectusmedical.com.

Forward-Looking Statements
This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause the business and financial results of Protectus Medical Devices, Inc. to differ materially from those currently anticipated, including the risk factors identified in Protectus Medical Devices, Inc.'s filings with the Securities and Exchange Commission.

About The Investor Relations Group, Inc.

The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of Alternative Public Offering (APO) companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company website at www.investorrelationsgroup.com.

Contact Information

  • Contact:

    John S. Salstrom, Ph.D.
    President and CEO
    Protectus Medical Devices, Inc.
    1-800-778-8438
    moreinfo@protectusmedical.com

    The Investor Relations Group
    212-825-3210
    Adam Holdsworth or James Carbonara